Please use this identifier to cite or link to this item: https://doi.org/10.18632/oncotarget.21019
Title: Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: A systematic review and meta-analysis
Authors: Soon, Y.Y 
Vellayappan, B 
Tey, J.C.S 
Leong, C.N 
Koh, W.Y 
Tham, I.W.K 
Keywords: epidermal growth factor receptor
Article
cancer chemotherapy
cancer control
cancer radiotherapy
cancer staging
cancer survival
esophagitis
exon
gene mutation
human
meta analysis
non small cell lung cancer
outcome assessment
overall survival
pneumonia
recurrence free survival
recurrence risk
skin toxicity
systematic review
treatment response
Issue Date: 2017
Citation: Soon, Y.Y, Vellayappan, B, Tey, J.C.S, Leong, C.N, Koh, W.Y, Tham, I.W.K (2017). Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: A systematic review and meta-analysis. Oncotarget 8 (65) : 109712-109722. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.21019
Abstract: Background: To determine if the presence of epidermal growth factor receptor (EGFR) sensitizing mutations improves tumor control and survival outcomes in patients with non-metastatic non-small cell lung cancer (NSCLC) who received definitive thoracic radiation therapy (TRT) with or without chemotherapy. Materials and Methods: We searched MEDLINE for eligible comparative studies which compared the outcomes of patients treated with definitive TRT according to EGFR mutation status. Meta-analysis was performed using random effects model. Outcomes of interest were tumor overall response rate (ORR), loco-regional (LRR), distant recurrence rates (DRR), relapse-free survival (RFS), overall survival (OS) and adverse events (AE). Results: We found seven studies including 537 patients with stage III NSCLC. Up to 45% of patients in the studies had mutations in exon 19 and 21. Patients harbouring EGFR sensitizing mutations had a trend towards improvement in ORR (risk ratio 1.17, 95% confidence interval 0.99-1.37, P = 0.06) compared to EGFR wild type status. There were no significant differences in LRR, DRR, RFS, OS and AE outcomes between the EGFR mutant and EGFR wild type groups. Conclusions: The presence of EGFR sensitizing mutations may improve tumour response rate but not survival in patients with localized NSCLC treated with definitive thoracic radiation therapy with or without chemotherapy. © Soon et al.
Source Title: Oncotarget
URI: https://scholarbank.nus.edu.sg/handle/10635/173798
ISSN: 19492553
DOI: 10.18632/oncotarget.21019
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_21019.pdf6.08 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

2
checked on Jan 24, 2021

Page view(s)

32
checked on Jan 15, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.